Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial

Table 1 Patient demographics and baseline clinical characteristics

Characteristics	n = 25
Age, years, median (range)	64 (33-71)
Male sex, n (%)	24 (96)
Etiology, n (%)
Hepatitis B infection	24 (96)
Others	1 (4)
ECOG performance status, n (%)
0	19 (76)
1	6 (24)
Child-Pugh class A, n (%)	25 (100)
BCLC C stage, n (%)	25 (100)
Site of recurrence, n (%)
Intrahepatic	19 (76)
Extrahepatic	6 (24)
Both Intra-Extrahepatic	2 (8)
Target tumor size, cm, median (range)	2.0 (1.0-7.4)
Tumor number, n (%)
1	19 (76)
2	5 (25)
3	1 (4)
Serum AFP ≥ 400 ng/mL, n (%)	3 (12)
Prior therapy, n (%)
Surgery	17 (68)
Ablation	9 (36)
TACE	13 (52)

AFP: α-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; TACE: Trans-arterial chemoembolization.